SEQUENTIAL METHOTREXATE, 5-FLUOROURACIL (5-FU), AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU ALONE FOR ADVANCED COLORECTAL-CANCER - A MULTIINSTITUTIONAL RANDOMIZED TRIAL

被引:0
作者
ABAD, A
GARCIA, P
GRAVALOS, C
TUSQUETS, I
FONT, A
PEREZ, G
CORTESFUNES, H
FABREGAT, X
BARNADAS, A
ROSELL, R
机构
[1] HOSP GEN GREGORIO MARANON,DEPT MED ONCOL,MADRID,SPAIN
[2] HOSP 12 OCTUBRE,DEPT MED ONCOL,E-28041 MADRID,SPAIN
[3] HOSP DEL MAR,DEPT MED ONCOL,BARCELONA,SPAIN
关键词
FLUOROURACIL; 5-FU; BIOCHEMICAL MODULATION; COLORECTAL CANCER;
D O I
10.1002/1097-0142(19950315)75:6<1238::AID-CNCR2820750605>3.0.CO;2-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The primary objective of this study was to compare the single-biochemical modulation of 5-fluorouracil (5-FU) and leucovorin with that of the double-biochemical modulation of methotrexate and leucovorin. Because of the Martin et al. study in which an experimental model showed similar effects of 5-FU at maximum tolerated doses to the modulation with leucovorin at standard doses, a third treatment arm of 5-FU alone was also studied. Methods. A randomized trial was performed using a 500-mg/m(2) intravenous (i.v,) 1-hour infusion of methotrexate, and 12 hours later, a 600-mg/m(2) i.v. bolus of 5-FU plus a 200-mg/m(2) i.v. 1-hour infusion of leucovorin (MFL) every 2 weeks versus 5-FU plus leucovorin at an equal dose and schedule (FL), versus a 1200-mg/m(2) i.v dose of 5-FU every 2 weeks. Of 186 patients included in the study, 178 were evaluable. Results. In a preliminary analysis with 94 evaluable patients, two significant statistical differences were shown. First, the toxicity rate of the 5-FU-alone (F) treatment arm was higher than that of the other arms (MFL vs. F, P = 0.0002; FL vs. F, P = 0.00001). Second, the median survival was worse in the F treatment arm with a rate of 12.6 months for the MFL and FL arms and 7.5 months for the F arm (P < 0.05). Considering these results, the F treatment arm was discontinued. The final results included 70 evaluable patients for MFL and 74 patients for FL. No difference was found in the distribution of prognostic factors. The response rates were 25.7% for MFL (95% CI, 16-37.5) and 14.8% for FL (95% CI, 7.6-25), (P = 0.1). The median survival was 14.3 months for patients treated with MFL and 12.3 months for those treated with FL. The hematologic toxicity was mild, with no grade 3/4 leukopenia in either treatment arm. The major nonhematologic toxicity in the MFL and FL treatment arms was ocular; nongrade 3/4 diarrhea also was observed. Conclusions. The results of MFL double-biochemical modulation failed to show a significant statistical difference from that of single-biochemical modulation for this dose and schedule.
引用
收藏
页码:1238 / 1244
页数:7
相关论文
共 50 条
  • [21] Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma - A phase III randomized study
    Tsavaris, Nicolas
    Kosmas, Christos
    Skopelitis, Helias
    Papadoniou, Nicitas
    Polyzos, Aristidis
    Zografos, George
    Adoniou, Efstathios
    Gryniatsos, John
    Felekouras, Evangelos
    Zacharakis, Michalis
    Sigala, Francheska
    Bacoyiannis, Christos
    Papastratis, George
    Papalambros, Efstathios
    CHEMOTHERAPY, 2007, 53 (04) : 282 - 291
  • [22] ADVANCED COLORECTAL-CARCINOMA - A PROSPECTIVE RANDOMIZED TRIAL OF SEQUENTIAL METHOTREXATE, 5-FLUOROURACIL, AND LEUCOVORIN VERSUS 5-FLUOROURACIL ALONE
    MACHIAVELLI, M
    LEONE, BA
    ROMERO, A
    RABINOVICH, MG
    VALLEJO, CT
    BIANCO, A
    PEREZ, JE
    RODRIGUEZ, R
    CUEVAS, MA
    ALVAREZ, LA
    CHACON, R
    HANNOIS, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (03): : 211 - 217
  • [23] Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer
    Romero, AO
    Perez, JE
    Cuevas, MA
    Lacava, JA
    Sabatini, CL
    Dominguez, ME
    Rodriguez, R
    Barbieri, MR
    Ortiz, EH
    Salvadori, MA
    Acuna, LAR
    Acuna, JMR
    Langhi, MJ
    Amato, S
    Machiavelli, MR
    Leone, BA
    Vallejo, CT
    Lorusso, V
    DeLena, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (01): : 94 - 98
  • [24] Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens
    Bajetta, E
    DiBartolomeo, M
    Somma, L
    DelVecchio, M
    Artale, S
    Zunino, F
    Bignami, P
    Magnani, E
    Buzzoni, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 687 - 690
  • [25] Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: A critical review of comparative studies
    Labianca, R
    Pessi, A
    Facendola, G
    Pirovano, M
    Luporini, G
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S7 - S12
  • [26] 120-HOUR 5-FLUOROURACIL (5-FU) CONTINUOUS INFUSION (CI) PLUS BCNU IN ADVANCED COLORECTAL-CANCER
    VILLARGRIMALT, A
    CANDEL, MT
    DELGADO, F
    GARCIAREINOSO, J
    SANCHIS, C
    VICIANO, V
    ASENCIO, F
    MARTINEZABAD, M
    AGUILO, J
    SANCHEZ, JJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (05): : 387 - 392
  • [27] Layered inorganic nanocomposites: A promising carrier for 5-fluorouracil (5-FU)
    Kevadiya, Bhavesh D.
    Patel, Tapan A.
    Jhala, Devendrasinh D.
    Thumbar, Rahul P.
    Brahmbhatt, Harshad
    Pandya, Maharshi P.
    Rajkumar, Shalini
    Jena, Prasant K.
    Joshi, Ghanshyam V.
    Gadhia, Pankaj K.
    Tripathi, C. B.
    Bajaj, Hari C.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 81 (01) : 91 - 101
  • [28] Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis
    Guo, Yuanbiao
    Shi, Min
    Shen, Xiaoheng
    Yang, Chen
    Yang, Liu
    Zhang, Jun
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 110 - 118
  • [29] A phase II experience with neoadjuvant irinotecan (CPT-II), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
    Bathe, Oliver F.
    Ernst, Scott
    Sutherland, Francis R.
    Dixon, Elijah
    Butts, Charles
    Bigam, David
    Holland, David
    Porter, Geoffrey A.
    Koppel, Jennifer
    Dowden, Scot
    BMC CANCER, 2009, 9
  • [30] Near fatal 5-FU gut toxicity post surgery - remarkable effect of high-dose sucralfate
    Toh, James Wei Tatt
    Morris, David
    Chen, Zhuoran
    Chen, Cindy
    JOURNAL OF CHEMOTHERAPY, 2015, 27 (03) : 188 - 192